France’s mid-sized pharmaceutical company, Ipsen SA, is looking to acquire late-stage product candidates, particularly in the US where its top-selling product, Somatuline (lanreotide), is expected to face generic competition in the near future, possibly by the end of this year.
But the company is also looking for early-stage candidates, business efficiencies, and to maximize the potential of its marketed products,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?